{"content":"<li class=\"n-box-item date-title\" data-end=\"1355374799\" data-start=\"1355288400\" data-txt=\"Wednesday, December 18, 2019\">Wednesday, December 12, 2012</li><li class=\"n-box-item sa-box-item\" data-id=\"717171\" data-ts=\"1355355389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDZ\" target=\"_blank\">NDZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/717171\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordion (NYSE:NDZ) postpones the release of its Q4 and FY12 financial results and conference...</a></h4><p>Nordion (NYSE:<a href=\"https://seekingalpha.com/symbol/NDZ\" title=\"Nordion Inc.\">NDZ</a>) postpones the release of its Q4 and FY12 financial results and conference call scheduled for December 18 and 19, respectively, saying it's initiated discussions to amend the terms of the company\u2019s credit facility. The discussions are related to the potential impact of ongoing litigation and the treatment of certain non-cash items. Shares <font color=\"red\">-5.4%</font> AH.</p><div class=\"tiny-share-widget\" data-id=\"717171\" data-linked=\"Nordion (NYSE:NDZ) postpones the release of its Q4 and FY12 financial results and conference...\" data-tweet=\"$NDZ - Nordion (NYSE:NDZ) postpones the release of its Q4 and FY12 financial results and conference call scheduled for December 18 and 19, respectively, saying it&#39;s initiated discussions to amend the terms of the company\u2019s credit facility. The discussio... https://seekingalpha.com/news/717171?source=tweet\" data-url=\"https://seekingalpha.com/news/717171\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"717071\" data-ts=\"1355352462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/717071\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo Health (NASDAQ:ENDP) pulls its 2013 guidance, saying it no longer expects to hit its EPS...</a></h4><p>Endo Health (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ENDP\" title=\"Endo International plc\">ENDP</a>) pulls its 2013 guidance, saying it no longer expects to hit its EPS target of between $5.20 - $5.40 on revenues of $3.0B - $3.2B. The company says it will provide updated 2013 guidance in early January. Street consensus estimates are for an EPS of $5.21 on revenue of $3.08B. Additionally, the company says that CEO David P. Holveck, will retire in 2013. Shares <font color=\"red\">-7.3%</font> AH.</p><div class=\"tiny-share-widget\" data-id=\"717071\" data-linked=\"Endo Health (NASDAQ:ENDP) pulls its 2013 guidance, saying it no longer expects to hit its EPS...\" data-tweet=\"$ENDP - Endo Health (NASDAQ:ENDP) pulls its 2013 guidance, saying it no longer expects to hit its EPS target of between $5.20 - $5.40 on revenues of $3.0B - $3.2B. The company says it will provide updated 2013 guidance in early January. Street consensus... https://seekingalpha.com/news/717071?source=tweet\" data-url=\"https://seekingalpha.com/news/717071\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"717041\" data-ts=\"1355351872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCC\" target=\"_blank\">ORCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/717041\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours top gainers, as of 5:15 p.m.: ORCC +7%. BBY +5%. KEM +4%. WWW +4%. MED +3%....</a></h4><b>After-hours top gainers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/ORCC' title='Online Resources Corporation'>ORCC</a> <font color=\"green\">+7%</font>. <a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color=\"green\">+5%</font>. <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color=\"green\">+4%</font>. <a href='https://seekingalpha.com/symbol/WWW' title='Wolverine World Wide Inc.'>WWW</a> <font color=\"green\">+4%</font>. <a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a> <font color=\"green\">+3%</font>. <br /><b>After-hours top losers:</b> <a href='https://seekingalpha.com/symbol/HRG' title='HRG Group, Inc.'>HRG</a> <font color=\"red\">-17%</font>. <a href='https://seekingalpha.com/symbol/GEF' title='Greif, Inc.'>GEF</a> <font color=\"red\">-7%</font>. <a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a> <font color=\"red\">-5%</font>. <a href='https://seekingalpha.com/symbol/SNV' title='Synovus Financial Corp.'>SNV</a> <font color=\"red\">-4%</font>. <a href='https://seekingalpha.com/symbol/PZE' title='Petrobras Argentina S.A.'>PZE</a> <font color=\"red\">-4%</font>.<div class=\"tiny-share-widget\" data-id=\"717041\" data-linked=\"After-hours top gainers, as of 5:15 p.m.: ORCC +7%. BBY +5%. KEM +4%. WWW +4%. MED +3%....\" data-tweet=\"$ORCC $ORCC-OLD $BBY - After-hours top gainers, as of 5:15 p.m.: ORCC +7%. BBY +5%. KEM +4%. WWW +4%. MED +3%. After-hours top losers: HRG -17%. GEF -7%. FMC -5%. SNV -4%. PZE -4%. https://seekingalpha.com/news/717041?source=tweet\" data-url=\"https://seekingalpha.com/news/717041\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"717031\" data-ts=\"1355351834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAM\" target=\"_blank\">SAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/717031\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boston Beer (NYSE:SAM) resumes trading, currently +7.2% at $122.50.</a></h4>Boston Beer (NYSE:<a href='https://seekingalpha.com/symbol/SAM' title='Boston Beer Co.'>SAM</a>) resumes trading, currently <font color=\"green\">+7.2%</font> at $122.50.<div class=\"tiny-share-widget\" data-id=\"717031\" data-linked=\"Boston Beer (NYSE:SAM) resumes trading, currently +7.2% at $122.50.\" data-tweet=\"$SAM - Boston Beer (NYSE:SAM) resumes trading, currently +7.2% at $122.50. https://seekingalpha.com/news/717031?source=tweet\" data-url=\"https://seekingalpha.com/news/717031\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716921\" data-ts=\"1355349171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DQ\" target=\"_blank\">DQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716921\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daqo New Energy (DQ +31.2%) jumped today after the Chinese polysilicon manufacturer announced a...</a></h4><p>Daqo New Energy (<a href=\"https://seekingalpha.com/symbol/DQ\" title=\"DAQO New Energy Corp.\">DQ</a> <font color=\"green\">+31.2%</font>) jumped today after the Chinese polysilicon manufacturer announced a change in the ratio for its American  Depositary Shares to ordinary shares to 1:25 from 1:5, effective Dec. 21.</p><div class=\"tiny-share-widget\" data-id=\"716921\" data-linked=\"Daqo New Energy (DQ +31.2%) jumped today after the Chinese polysilicon manufacturer announced a...\" data-tweet=\"$DQ - Daqo New Energy (DQ +31.2%) jumped today after the Chinese polysilicon manufacturer announced a change in the ratio for its American Depositary Shares to ordinary shares to 1:25 from 1:5, effective Dec. 21. https://seekingalpha.com/news/716921?source=tweet\" data-url=\"https://seekingalpha.com/news/716921\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716661\" data-ts=\"1355345866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMC\" target=\"_blank\">FMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716661\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FMC Corp. (FMC +4.8%) says it expects to exceed $5B in sales by 2015, exceeding its earlier...</a></h4><p>FMC Corp. (<a href=\"https://seekingalpha.com/symbol/FMC\" title=\"FMC Corporation\">FMC</a> <font color=\"green\">+4.8%</font>) says it expects to exceed $5B in sales by 2015, exceeding its earlier revenue goal by at least 10% and representing more than twice the chemical company's 2009 revenue. KeyBanc believes FMC is an <a href=\"http://finance.yahoo.com/news/fmc-says-beat-long-term-190641811.html\" target=\"_blank\">attractive mid-cap growth story</a>; the firm raises its 2013 earnings forecasts  based on those expectations and hikes its price target to $71  from $67. (<a href=\"https://seekingalpha.com/currents/post/712801\" target=\"_blank\">also</a>)</p><div class=\"tiny-share-widget\" data-id=\"716661\" data-linked=\"FMC Corp. (FMC +4.8%) says it expects to exceed $5B in sales by 2015, exceeding its earlier...\" data-tweet=\"$FMC - FMC Corp. (FMC +4.8%) says it expects to exceed $5B in sales by 2015, exceeding its earlier revenue goal by at least 10% and representing more than twice the chemical company&#39;s 2009 revenue. KeyBanc believes FMC is an attractive mid-cap growth st... https://seekingalpha.com/news/716661?source=tweet\" data-url=\"https://seekingalpha.com/news/716661\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716641\" data-ts=\"1355345258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANDV\" target=\"_blank\">ANDV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716641\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">In its analyst day presentation, Tesoro (TSO -2.2%) projects $455M in 2013 capital spending...</a></h4><p>In its analyst day <a href=\"http://www.sec.gov/Archives/edgar/data/50104/000005010412000090/tsoanalystday2012vfinal2.htm\" target=\"_blank\">presentation</a>, Tesoro (TSO <font color=\"red\">-2.2%</font>) projects $455M in 2013 capital spending after coming in at $535M this year. TSO says it seeks to maintain a minimum cash balance of $600M-$750M, and cites a drive towards investment-grade credit a top priority. Says returns on its large capital projects are exceeding expectations; believes improvements are not fully reflected in the share price.</p><div class=\"tiny-share-widget\" data-id=\"716641\" data-linked=\"In its analyst day presentation, Tesoro (TSO -2.2%) projects $455M in 2013 capital spending...\" data-tweet=\"$ANDV - In its analyst day presentation, Tesoro (TSO -2.2%) projects $455M in 2013 capital spending after coming in at $535M this year. TSO says it seeks to maintain a minimum cash balance of $600M-$750M, and cites a drive towards investment-grade credi... https://seekingalpha.com/news/716641?source=tweet\" data-url=\"https://seekingalpha.com/news/716641\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716601\" data-ts=\"1355345085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSON\" target=\"_blank\">MSON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716601\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Misonix (MSON +7.2%) trades up today after terminating its distribution agreement with Aesculap...</a></h4><p>Misonix (<a href=\"https://seekingalpha.com/symbol/MSON\" title=\"MISONIX, Inc.\">MSON</a> <font color=\"green\">+7.2%</font>) trades up today after terminating its distribution agreement with Aesculap for the Misonix BoneScalpel Ultrasonic Bone Cutting System. As part of the termination, <a href=\"https://seekingalpha.com/symbol/MSON\" title=\"MISONIX, Inc.\">MSON</a> purchased all of Aesculap's hardware inventory, for which it plans to supplement its own growing proprietary sales push with equipment for sales, demonstration and evaluation purposes.</p><div class=\"tiny-share-widget\" data-id=\"716601\" data-linked=\"Misonix (MSON +7.2%) trades up today after terminating its distribution agreement with Aesculap...\" data-tweet=\"$MSON - Misonix (MSON +7.2%) trades up today after terminating its distribution agreement with Aesculap for the Misonix BoneScalpel Ultrasonic Bone Cutting System. As part of the termination, MSON purchased all of Aesculap&#39;s hardware inventory, for whic... https://seekingalpha.com/news/716601?source=tweet\" data-url=\"https://seekingalpha.com/news/716601\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716501\" data-ts=\"1355343358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVD\" target=\"_blank\">AVD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716501\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Despite keeping a Strong Buy rating on American Vanguard (AVD -9.8%), Feltl &amp;amp;&amp;nbsp;Co. notes...</a></h4><p>Despite keeping a Strong Buy rating on American Vanguard (<a href=\"https://seekingalpha.com/symbol/AVD\" title=\"American Vanguard Corporation\">AVD</a> <font color=\"red\">-9.8%</font>), Feltl &amp; Co. notes the ag product company's unique niche in the corn soil insecticide market <a href=\"http://online.wsj.com/article/BT-CO-20121212-711659.html\" target=\"_blank\">could come under threat</a> as \"several major companies may soon enter or significantly expand their offerings... the possibility of looming competition on this front may start to weigh on the stock.\"</p><div class=\"tiny-share-widget\" data-id=\"716501\" data-linked=\"Despite keeping a Strong Buy rating on American Vanguard (AVD -9.8%), Feltl &amp;amp; Co. notes the...\" data-tweet=\"$AVD - Despite keeping a Strong Buy rating on American Vanguard (AVD -9.8%), Feltl &amp; Co. notes the ag product company&#39;s unique niche in the corn soil insecticide market could come under threat as &quot;several major companies may soon enter or significantly ... https://seekingalpha.com/news/716501?source=tweet\" data-url=\"https://seekingalpha.com/news/716501\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716431\" data-ts=\"1355341585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPXC\" target=\"_blank\">SPXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716431\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters reports SPX (SPW -0.5%) has outbid private equity firms competing to buy Gardner Denver...</a></h4><p>Reuters reports SPX (SPW <font color=\"red\">-0.5%</font>) has <a href=\"http://www.reuters.com/article/2012/12/12/gardnerdenver-spx-idUSL1E8NCC3Q20121212\" target=\"_blank\">outbid</a> private equity firms competing to buy Gardner Denver (<a href=\"https://seekingalpha.com/symbol/GDI\" title=\"Gardner Denver Holdings, Inc.\">GDI</a> <font color=\"green\">+5.7%</font>) by a wide margin, offering to pay more than $4B. The SPX offer was so much higher that GDI reportedly cancelled management meetings with other bidders that were initially set for this week and did not even seek second-round offers.</p><div class=\"tiny-share-widget\" data-id=\"716431\" data-linked=\"Reuters reports SPX (SPW -0.5%) has outbid private equity firms competing to buy Gardner Denver...\" data-tweet=\"$SPXC $SPXC $GDI - Reuters reports SPX (SPW -0.5%) has outbid private equity firms competing to buy Gardner Denver (GDI +5.7%) by a wide margin, offering to pay more than $4B. The SPX offer was so much higher that GDI reportedly cancelled management mee... https://seekingalpha.com/news/716431?source=tweet\" data-url=\"https://seekingalpha.com/news/716431\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716421\" data-ts=\"1355341509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716421\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral...</a></h4><p>Alnylam Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/ALNY\" title=\"Alnylam Pharmaceuticals, Inc.\">ALNY</a> <font color=\"green\">+4%</font>) trades up after Piper Jaffray raised its rating to Neutral and increased its price target from $19 to $25. Piper notes that with the Tekmira litigation behind them, <a href=\"https://seekingalpha.com/symbol/ALNY\" title=\"Alnylam Pharmaceuticals, Inc.\">ALNY</a> can now focus more on clinical progress. Specifically, the firm expects the drug developer to have Phase II data on its ALN-TTR02 this summer to prepare for pivotal studies by year-end, adding that <a href=\"https://seekingalpha.com/symbol/ALNY\" title=\"Alnylam Pharmaceuticals, Inc.\">ALNY</a> also plans to file applications with the FDA on sub-cutaneous hemophilia therapy formulations of ALN-TTR02 and ALN-AT3.</p><div class=\"tiny-share-widget\" data-id=\"716421\" data-linked=\"Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral...\" data-tweet=\"$ALNY - Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral and increased its price target from $19 to $25. Piper notes that with the Tekmira litigation behind them, ALNY can now focus more on clinical progress.... https://seekingalpha.com/news/716421?source=tweet\" data-url=\"https://seekingalpha.com/news/716421\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716411\" data-ts=\"1355341284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACMP\" target=\"_blank\">ACMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716411\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">S&amp;amp;P and Moody&#39;s weigh in to affirm the credit rating of Access Midstream (ACMP -4.7%) after...</a></h4><a href=\"http://www.reuters.com/article/2012/12/12/idUSWNA093520121212\" target=\"_blank\">S&amp;P</a> and <a href=\"http://www.reuters.com/article/2012/12/12/idUSMDY79srQ620121212\" target=\"_blank\">Moody's</a> weigh in to affirm the credit rating of Access Midstream (<a href='https://seekingalpha.com/symbol/ACMP' title='Access Midstream Partners, L.P.'>ACMP</a> <font color=\"red\">-4.7%</font>) after the natural gas partnership <a href=\"https://seekingalpha.com/currents/post/714501\" target=\"_blank\">buys</a> most of Chesapeake's (<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color=\"red\">-0.3%</font>) remaining natural gas and crude oil gathering assets for $2.16B and Williams Cos. (<a href='https://seekingalpha.com/symbol/WMB' title='Williams Companies Inc'>WMB</a> <font color=\"red\">-0.4%</font>) <a href=\"https://seekingalpha.com/currents/post/714511\" target=\"_blank\">acquires</a> a stake in ACMP for $2.4B. S&amp;P also <a href=\"http://www.reuters.com/article/2012/12/12/idUSWNA093720121212\" target=\"_blank\">affirms</a> WMB&rsquo;s rating, while Fitch says it <a href=\"http://www.reuters.com/article/2012/12/12/idUSWNA094320121212\" target=\"_blank\">expects no rating change</a>.<div class=\"tiny-share-widget\" data-id=\"716411\" data-linked=\"S&amp;amp;P and Moody&#39;s weigh in to affirm the credit rating of Access Midstream (ACMP -4.7%) after...\" data-tweet=\"$ACMP $ACMP $CHK - S&amp;P and Moody&#39;s weigh in to affirm the credit rating of Access Midstream (ACMP -4.7%) after the natural gas partnership buys most of Chesapeake&#39;s (CHK -0.3%) remaining natural gas and crude oil gathering assets for $2.16B and Williams... https://seekingalpha.com/news/716411?source=tweet\" data-url=\"https://seekingalpha.com/news/716411\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716291\" data-ts=\"1355339583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWSH\" target=\"_blank\">SWSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716291\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Swisher Hygiene (SWSH +10%) moves higher today after the Nasdaq Hearings Panel reviewed its plan...</a></h4><p>Swisher Hygiene (<a href=\"https://seekingalpha.com/symbol/SWSH\" title=\"Swisher Hygiene, Inc\">SWSH</a> <font color=\"green\">+10%</font>) moves higher today after the Nasdaq Hearings Panel reviewed its plan of compliance to complete its public filings and granted <a href=\"https://seekingalpha.com/symbol/SWSH\" title=\"Swisher Hygiene, Inc\">SWSH</a>'s request to remain listed. The decision however, is subject to <a href=\"https://seekingalpha.com/symbol/SWSH\" title=\"Swisher Hygiene, Inc\">SWSH</a> meeting specific conditions for continued listing.</p><div class=\"tiny-share-widget\" data-id=\"716291\" data-linked=\"Swisher Hygiene (SWSH +10%) moves higher today after the Nasdaq Hearings Panel reviewed its plan...\" data-tweet=\"$SWSH - Swisher Hygiene (SWSH +10%) moves higher today after the Nasdaq Hearings Panel reviewed its plan of compliance to complete its public filings and granted SWSH&#39;s request to remain listed. The decision however, is subject to SWSH meeting specific ... https://seekingalpha.com/news/716291?source=tweet\" data-url=\"https://seekingalpha.com/news/716291\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716281\" data-ts=\"1355339415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DWDP\" target=\"_blank\">DWDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716281\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DuPont (DD +2.2%) plans to spend less on capital projects next year than initially planned due...</a></h4><p>DuPont (DD <font color=\"green\">+2.2%</font>) <a href=\"http://www.reuters.com/article/2012/12/12/us-dupont-spending-idUSBRE8BB1EF20121212\" target=\"_blank\">plans to spend less</a> on capital projects next year than initially planned due to uncertainty about the fiscal cliff, holding capex at ~$1.8B and delaying some projects, CEO Ellen Kullman tells Reuters. After yesterday's close, DD issued a <a href=\"https://seekingalpha.com/currents/post/714181\" target=\"_blank\">better-than-expected forecast</a> for 2013 and announced a $1B stock repurchase program.</p><div class=\"tiny-share-widget\" data-id=\"716281\" data-linked=\"DuPont (DD +2.2%) plans to spend less on capital projects next year than initially planned due...\" data-tweet=\"$DWDP $DD - DuPont (DD +2.2%) plans to spend less on capital projects next year than initially planned due to uncertainty about the fiscal cliff, holding capex at ~$1.8B and delaying some projects, CEO Ellen Kullman tells Reuters. After yesterday&#39;s clos... https://seekingalpha.com/news/716281?source=tweet\" data-url=\"https://seekingalpha.com/news/716281\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716221\" data-ts=\"1355338250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABIO\" target=\"_blank\">ABIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716221\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the...</a></h4><p>Arca Biopharma (<a href=\"https://seekingalpha.com/symbol/ABIO\" title=\"ARCA biopharma, Inc.\">ABIO</a> <font color=\"green\">+30%</font>) soars today after announcing that a paper was published in the <em>European Journal of Heart Failure</em> which presented data demonstrating that patients with established atrial fibrillation who received <a href=\"https://seekingalpha.com/symbol/ABIO\" title=\"ARCA biopharma, Inc.\">ABIO</a>'s Gencaro had improvements in heart failure clinical endpoints. The data also showed that Gencaro made it more likely for patients to achieve ventricular rate control, and that Gencaro improved cardiovascular clinical endpoints for those patients who did achieve rate control.</p><div class=\"tiny-share-widget\" data-id=\"716221\" data-linked=\"Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the...\" data-tweet=\"$ABIO - Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the European Journal of Heart Failure which presented data demonstrating that patients with established atrial fibrillation who received ABIO&#39;s Gencaro had imp... https://seekingalpha.com/news/716221?source=tweet\" data-url=\"https://seekingalpha.com/news/716221\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716191\" data-ts=\"1355337131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEF\" target=\"_blank\">GEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716191\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greif (GEF +9.1%) pops today after its FQ4 bottom line beat estimates late yesterday. Net...</a></h4><p>Greif (<a href=\"https://seekingalpha.com/symbol/GEF\" title=\"Greif, Inc.\">GEF</a> <font color=\"green\">+9.1%</font>) pops today after its <a href=\"https://seekingalpha.com/market_currents/post/714551\" target=\"_blank\">FQ4 bottom line beat estimates</a> late yesterday. Net earnings rose 27% as the packaging company posted lower restructuring costs. Going into the new year, the company anticipates a slight increase in volumes and margin improvement due to stabilizing raw material costs, and an improvement in operating performance as recent containerboard price increases take affect.</p><div class=\"tiny-share-widget\" data-id=\"716191\" data-linked=\"Greif (GEF +9.1%) pops today after its FQ4 bottom line beat estimates late yesterday. Net...\" data-tweet=\"$GEF - Greif (GEF +9.1%) pops today after its FQ4 bottom line beat estimates late yesterday. Net earnings rose 27% as the packaging company posted lower restructuring costs. Going into the new year, the company anticipates a slight increase in volumes a... https://seekingalpha.com/news/716191?source=tweet\" data-url=\"https://seekingalpha.com/news/716191\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716111\" data-ts=\"1355334496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPEN\" target=\"_blank\">OPEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716111\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OpenTable (OPEN +2.4%) is rallying after JPMorgan launches coverage with an Overweight and $53...</a></h4>OpenTable (<a href='https://seekingalpha.com/symbol/OPEN' title='OpenTable, Inc.'>OPEN</a> <font color='green'>+2.4%</font>) is rallying after JPMorgan <a href=\"http://www.marketwatch.com/story/wednesdays-biggest-gaining-and-declining-stocks-2012-12-12\" target=\"_blank\">launches coverage</a> with an Overweight and $53 PT. \"OpenTable&rsquo;s 48% penetration of North American reservation-taking restaurants gives the company a sizable first-mover advantage,\" says analyst Kaizad Gotla. He expects NA restaurant adds to slow, but sees seated diner growth accelerating due to search, mobile, and social networking efforts, and an ongoing shift from phone-based to online reservations (still only 15%-20% of total).<div class=\"tiny-share-widget\" data-id=\"716111\" data-linked=\"OpenTable (OPEN +2.4%) is rallying after JPMorgan launches coverage with an Overweight and $53...\" data-tweet=\"$OPEN - OpenTable (OPEN +2.4%) is rallying after JPMorgan launches coverage with an Overweight and $53 PT. &quot;OpenTable&amp;rsquo;s 48% penetration of North American reservation-taking restaurants gives the company a sizable first-mover advantage,&quot; says analy... https://seekingalpha.com/news/716111?source=tweet\" data-url=\"https://seekingalpha.com/news/716111\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716101\" data-ts=\"1355334428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716101\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">As a condition of Medicines Company&#39;s (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence...</a></h4><p>As a condition of Medicines Company's (<a href=\"https://seekingalpha.com/symbol/MDCO\" title=\"The Medicines Company\">MDCO</a> <font color=\"green\">+1.9%</font>) <a href=\"https://seekingalpha.com/market_currents/post/716061\" target=\"_blank\">acquisition</a> of Incline Therapeutics, Cadence Pharmaceuticals (CADX <font color=\"green\">+4.9%</font>) has <a href=\"https://seekingalpha.com/article/1059941-cadx-to-receive-14-5m-or-0-15-share-in-non-dilutive-funds\" target=\"_blank\">agreed to terminate</a> its exclusive option to acquire Incline. Upon <a href=\"https://seekingalpha.com/symbol/MDCO\" title=\"The Medicines Company\">MDCO</a>'s closing of the deal, CADX will receive around $13M in termination fees and roughly $1.5M for its Incline stake as well as a pro-rated share of future milestone payments.</p><div class=\"tiny-share-widget\" data-id=\"716101\" data-linked=\"As a condition of Medicines Company&#39;s (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence...\" data-tweet=\"$MDCO $MDCO $MNK - As a condition of Medicines Company&#39;s (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence Pharmaceuticals (CADX +4.9%) has agreed to terminate its exclusive option to acquire Incline. Upon MDCO&#39;s closing of the deal, CADX will r... https://seekingalpha.com/news/716101?source=tweet\" data-url=\"https://seekingalpha.com/news/716101\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716071\" data-ts=\"1355334321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716071\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday top 10 gainers: YMI +77%. DSTI +73%. OTCQB:TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL...</a></h4><b>Midday top 10 gainers:</b> <a href='https://seekingalpha.com/symbol/YMI' title=''>YMI</a> <font color=\"green\">+77%</font>. <a href='https://seekingalpha.com/symbol/DSTI' title='DayStar Technologies, Inc.'>DSTI</a> <font color=\"green\">+73%</font>. <a href='https://seekingalpha.com/symbol/TELK' title='Telik, Inc.'>OTCQB:TELK</a> <font color=\"green\">+25%</font>. <a href='https://seekingalpha.com/symbol/LDK' title='LDK Solar Co., Ltd.'>LDK</a> <font color=\"green\">+21%</font>. <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color=\"green\">+23%</font>. <a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color=\"green\">+21%</font>. <a href='https://seekingalpha.com/symbol/TSL' title='Trina Solar Limited'>TSL</a> <font color=\"green\">+20%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color=\"green\">+19%</font>. <a href='https://seekingalpha.com/symbol/CBMX' title='CombiMatrix Corporation'>CBMX</a> <font color=\"green\">+14%</font>. <a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a> <font color=\"green\">+17%</font>. <br /><b>Midday top 10 Losers:</b> RSOL <font color=\"red\">-14%</font>. <a href='https://seekingalpha.com/symbol/CENT' title='Central Garden & Pet Company'>CENT</a> <font color=\"red\">-13%</font>. <a href='https://seekingalpha.com/symbol/ACUR' title='Acura Pharmaceuticals, Inc.'>OTC:ACUR</a> <font color=\"red\">-11%</font>. <a href='https://seekingalpha.com/symbol/TAS' title='Tasman Metals Ltd.'>TAS</a> <font color=\"red\">-11%</font>. <a href='https://seekingalpha.com/symbol/CATO' title='The Cato Corporation'>CATO</a> <font color=\"red\">-10%</font>. <a href='https://seekingalpha.com/symbol/CRWS' title='Crown Crafts, Inc.'>CRWS</a> <font color=\"red\">-9%</font>. <a href='https://seekingalpha.com/symbol/AVD' title='American Vanguard Corporation'>AVD</a> <font color=\"red\">-9%</font>. <a href='https://seekingalpha.com/symbol/CRL' title='Charles River Laboratories International, Inc.'>CRL</a> <font color=\"red\">-8%</font>. AXK <font color=\"red\">-8%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color=\"red\">-8%</font>.<div class=\"tiny-share-widget\" data-id=\"716071\" data-linked=\"Midday top 10 gainers: YMI +77%. DSTI +73%. OTCQB:TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL...\" data-tweet=\"$GILD $GILD $DSTI - Midday top 10 gainers: YMI +77%. DSTI +73%. OTCQB:TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%. Midday top 10 Losers: RSOL -14%. CENT -13%. OTC:ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. C... https://seekingalpha.com/news/716071?source=tweet\" data-url=\"https://seekingalpha.com/news/716071\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716061\" data-ts=\"1355333823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716061\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medicines Company (MDCO +1.9%) moves up today after agreeing to acquire privately held Incline...</a></h4><p>Medicines Company (<a href=\"https://seekingalpha.com/symbol/MDCO\" title=\"The Medicines Company\">MDCO</a> <font color=\"green\">+1.9%</font>) moves up today after agreeing to acquire privately held  Incline Therapeutics for $185M plus potential milestone payments. The acquisition gives <a href=\"https://seekingalpha.com/symbol/MDCO\" title=\"The Medicines Company\">MDCO</a> access to the development of a disposable and needleless patient-controlled analgesia system for postoperative pain management in hospitals. Additionally, the company also reached a licensing agreement with Bristol-Myers Squibb (<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a> <font color=\"green\">+0.6%</font>) on its Recothrom topical treatment to control bleeding during surgery.</p><div class=\"tiny-share-widget\" data-id=\"716061\" data-linked=\"Medicines Company (MDCO +1.9%) moves up today after agreeing to acquire privately held Incline...\" data-tweet=\"$MDCO $MDCO $BMY - Medicines Company (MDCO +1.9%) moves up today after agreeing to acquire privately held Incline Therapeutics for $185M plus potential milestone payments. The acquisition gives MDCO access to the development of a disposable and needlele... https://seekingalpha.com/news/716061?source=tweet\" data-url=\"https://seekingalpha.com/news/716061\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"716041\" data-ts=\"1355333670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNC\" target=\"_blank\">SYNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/716041\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synacor (SYNC +7.1%) is higher after announcing a deal to provide start pages for Lenovo...</a></h4><p>Synacor (<a href=\"https://seekingalpha.com/symbol/SYNC\" title=\"Synacor\">SYNC</a> <font color=\"green\">+7.1%</font>) is higher after announcing a deal to provide start pages for Lenovo consumer PCs. The company, which has been heavily touted by the infamous Jonathan Lebed, <a target=\"_blank\" href=\"http://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1355346000000&amp;chddm=43821&amp;chls=IntervalBasedLine&amp;q=NASDAQ:SYNC&amp;ntsp=0&amp;ei=5b7IUOieIoiZiQKOmAE\">remains well off</a> its July highs.</p><div class=\"tiny-share-widget\" data-id=\"716041\" data-linked=\"Synacor (SYNC +7.1%) is higher after announcing a deal to provide start pages for Lenovo...\" data-tweet=\"$SYNC - Synacor (SYNC +7.1%) is higher after announcing a deal to provide start pages for Lenovo consumer PCs. The company, which has been heavily touted by the infamous Jonathan Lebed, remains well off its July highs. https://seekingalpha.com/news/716041?source=tweet\" data-url=\"https://seekingalpha.com/news/716041\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715941\" data-ts=\"1355332413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLTHF\" target=\"_blank\">TLTHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715941\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Talison Lithium (OTC:TLTHF) calls off buyout talks with Rockwood Holdings (ROC +1.8%) after...</a></h4>Talison Lithium (<a href='https://seekingalpha.com/symbol/TLTHF' title='Talison Lithium Ltd'>OTC:TLTHF</a>) <a href=\"http://www.reuters.com/article/2012/12/12/us-talison-tianqi-idUSBRE8BB0WD20121212\" target=\"_blank\">calls off buyout talks</a> with Rockwood Holdings (<a href='https://seekingalpha.com/symbol/ROC' title='Rockwood Holdings, Inc.'>ROC</a> <font color=\"green\">+1.8%</font>) after backing a <a href=\"https://seekingalpha.com/currents/post/679691\" target=\"_blank\">sweetened takeover bid</a> from Chengdu Tianqi. ROC had offered to buy Talison for C$6.50/share, below Tianqi's revised C$7.50 offer; the ROC offer valued Talison at C$724M, while Tianqi's offer values the  miner at C$847M.<div class=\"tiny-share-widget\" data-id=\"715941\" data-linked=\"Talison Lithium (OTC:TLTHF) calls off buyout talks with Rockwood Holdings (ROC +1.8%) after...\" data-tweet=\"$TLTHF $TLTHF $ROC - Talison Lithium (OTC:TLTHF) calls off buyout talks with Rockwood Holdings (ROC +1.8%) after backing a sweetened takeover bid from Chengdu Tianqi. ROC had offered to buy Talison for C$6.50/share, below Tianqi&#39;s revised C$7.50 offer; ... https://seekingalpha.com/news/715941?source=tweet\" data-url=\"https://seekingalpha.com/news/715941\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715931\" data-ts=\"1355332398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCMP\" target=\"_blank\">SCMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715931\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sucampo Pharmaceuticals (SCMP +4.2%) moves higher today after earlier announcing its...</a></h4><p>Sucampo Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/SCMP\" title=\"Sucampo Pharmaceuticals, Inc.\">SCMP</a> <font color=\"green\">+4.2%</font>) moves higher today after earlier announcing its supplemental new drug application for Rescula, a treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, has been approved by the FDA. According to the labeling, the treatment may be used as a first-line agent or in tandem with other topical ophthalmic drugs.</p><div class=\"tiny-share-widget\" data-id=\"715931\" data-linked=\"Sucampo Pharmaceuticals (SCMP +4.2%) moves higher today after earlier announcing its...\" data-tweet=\"$SCMP - Sucampo Pharmaceuticals (SCMP +4.2%) moves higher today after earlier announcing its supplemental new drug application for Rescula, a treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, has be... https://seekingalpha.com/news/715931?source=tweet\" data-url=\"https://seekingalpha.com/news/715931\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715871\" data-ts=\"1355330581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMOAF\" target=\"_blank\">TMOAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715871\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TomTom (OTCPK:TMOAF) is up 6.1% in Amsterdam after a Rabobank analyst claims there&#39;s a 30%...</a></h4><p>TomTom (<a href=\"https://seekingalpha.com/symbol/TMOAF\" title=\"Tomtom NV\">OTCPK:TMOAF</a>) is <font color=\"green\">up 6.1%</font> in Amsterdam after a Rabobank analyst <a target=\"_blank\" href=\"http://www.bloomberg.com/news/2012-12-12/tomtom-rises-as-rabo-forsees-move-by-apple-for-takeover.html\">claims there's a 30% chance</a> Apple (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a>) will try to buy the company to help fix Apple Maps - TomTom <a target=\"_blank\" href=\"http://www.engadget.com/2012/06/11/apple-tomtom-ios-6-maps/\">currently provides</a> mapping/navigation data for the much-criticized app. Navigation services rival Telenav (<a href=\"https://seekingalpha.com/symbol/TNAV\" title=\"Telenav, Inc.\">TNAV</a> <font color=\"green\">+4.7%</font>) appears to be rallying on the news, but PND rival Garmin (<a href=\"https://seekingalpha.com/symbol/GRMN\" title=\"Garmin Ltd.\">GRMN</a> <font color=\"red\">-3.3%</font>) is lower. TomTom CEO Harold Goddjin said in October his company plans to remain independent.</p><div class=\"tiny-share-widget\" data-id=\"715871\" data-linked=\"TomTom (OTCPK:TMOAF) is up 6.1% in Amsterdam after a Rabobank analyst claims there&#39;s a 30%...\" data-tweet=\"$TMOAF $TMOAF $AAPL - TomTom (OTCPK:TMOAF) is up 6.1% in Amsterdam after a Rabobank analyst claims there&#39;s a 30% chance Apple (NASDAQ:AAPL) will try to buy the company to help fix Apple Maps - TomTom currently provides mapping/navigation data for the mu... https://seekingalpha.com/news/715871?source=tweet\" data-url=\"https://seekingalpha.com/news/715871\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715861\" data-ts=\"1355330500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715861\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The...</a></h4><p>Acadia Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/ACAD\" title=\"ACADIA Pharmaceuticals Inc.\">ACAD</a> <font color=\"green\">+10.6%</font>) jumps after announcing an $86.4M private placement. The securities are to be sold at $4.43 per share, and will be used primarily to support completion of it's Phase III pimavanserin program, including a planned confirmatory Phase III pivotal trial in Parkinson's disease psychosis.</p><div class=\"tiny-share-widget\" data-id=\"715861\" data-linked=\"Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The...\" data-tweet=\"$ACAD - Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The securities are to be sold at $4.43 per share, and will be used primarily to support completion of it&#39;s Phase III pimavanserin program, including a plann... https://seekingalpha.com/news/715861?source=tweet\" data-url=\"https://seekingalpha.com/news/715861\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715811\" data-ts=\"1355329683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDK\" target=\"_blank\">LDK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715811\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Debt-laden, cash-burning LDK Solar (LDK +16.3%) says it has &quot;entered into discussions with...</a></h4><p>Debt-laden, cash-burning LDK Solar (<a href=\"https://seekingalpha.com/symbol/LDK\" title=\"LDK Solar Co., Ltd.\">LDK</a> <font color=\"green\">+16.3%</font>) says it has \"entered into discussions with certain creditors to obtain additional flexibility,\" and has hired Citi to assist in the process. Shares were already posting huge gains prior to the announcement, fueled by <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/715271\">reports</a> the Chinese government is ramping its solar subsidies and installation targets. Other big winners: <a href=\"https://seekingalpha.com/symbol/TSL\" title=\"Trina Solar Limited\">TSL</a> <font color=\"green\">+15.8%</font>. <a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a> <font color=\"green\">+17.1%</font>. <a href=\"https://seekingalpha.com/symbol/JASO\" title=\"JA Solar Holdings, Co., Ltd.\">JASO</a> <font color=\"green\">+13.2%</font>. <a href=\"https://seekingalpha.com/symbol/SOL\" title=\"ReneSola Ltd.\">SOL</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/STP\" title=\"Suntech Power Holdings Co., Ltd.\">STP</a> <font color=\"green\">+7.9%</font>. <a href=\"https://seekingalpha.com/symbol/JKS\" title=\"JinkoSolar Holding Co., Ltd.\">JKS</a> <font color=\"green\">+11.2%</font> - previous. U.S. vendors First Solar (<a href=\"https://seekingalpha.com/symbol/FSLR\" title=\"First Solar, Inc.\">FSLR</a> <font color=\"green\">+4.1%</font>) and SunPower (<a href=\"https://seekingalpha.com/symbol/SPWR\" title=\"SunPower Corporation\">SPWR</a> <font color=\"green\">+6.2%</font>) are also higher. (<a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/696071\">LDK's Q4 guidance</a>)</p><div class=\"tiny-share-widget\" data-id=\"715811\" data-linked=\"Debt-laden, cash-burning LDK Solar (LDK +16.3%) says it has &quot;entered into discussions with...\" data-tweet=\"$LDK $LDK $TSL - Debt-laden, cash-burning LDK Solar (LDK +16.3%) says it has &quot;entered into discussions with certain creditors to obtain additional flexibility,&quot; and has hired Citi to assist in the process. Shares were already posting huge gains prior to... https://seekingalpha.com/news/715811?source=tweet\" data-url=\"https://seekingalpha.com/news/715811\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715801\" data-ts=\"1355329289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IO\" target=\"_blank\">IO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715801\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two firms initiate coverage of Ion Geophysical (IO +8.6%): Barrington starts at Outperform,...</a></h4><p>Two firms initiate coverage of Ion Geophysical (<a href=\"https://seekingalpha.com/symbol/IO\" title=\"ION Geophysical Corporation\">IO</a> <font color=\"green\">+8.6%</font>): Barrington starts at Outperform, expecting IO to <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/12/12/3166986/update-barrington-research-initiates-coverage-on-ion-geo\" target=\"_blank\">benefit from increased demand</a> driven by complex and unconventional reservoirs, while Dougherty starts with a Buy rating, seeing strong demand for IO's multi-client and data processing services driving top and bottom line growth in excess of 15% and 25%, respectively.</p><div class=\"tiny-share-widget\" data-id=\"715801\" data-linked=\"Two firms initiate coverage of Ion Geophysical (IO +8.6%): Barrington starts at Outperform,...\" data-tweet=\"$IO - Two firms initiate coverage of Ion Geophysical (IO +8.6%): Barrington starts at Outperform, expecting IO to benefit from increased demand driven by complex and unconventional reservoirs, while Dougherty starts with a Buy rating, seeing strong dema... https://seekingalpha.com/news/715801?source=tweet\" data-url=\"https://seekingalpha.com/news/715801\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715791\" data-ts=\"1355329127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAP\" target=\"_blank\">AAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715791\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advance Auto Parts (AAP +1.8%) ratchets higher with takeover rumors flying around again over the...</a></h4>Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color=\"green\">+1.8%</font>) ratchets higher with <a href=\"http://www.streetinsider.com/Rumors/Advance+Auto+Parts+%28AAP%29+Pops+on+Takeover+Chatter/7942697.html\" target=\"_blank\">takeover rumors</a> flying around again over the automotive parts seller. Blackstone Group was hired last month to gauge interest with most analysts seeing a combined P-E bid as the most likely path to a successful bid. With the company only sitting on a reasonable $600M in long-term debt, a leveraged buyout is on the table.<div class=\"tiny-share-widget\" data-id=\"715791\" data-linked=\"Advance Auto Parts (AAP +1.8%) ratchets higher with takeover rumors flying around again over the...\" data-tweet=\"$AAP - Advance Auto Parts (AAP +1.8%) ratchets higher with takeover rumors flying around again over the automotive parts seller. Blackstone Group was hired last month to gauge interest with most analysts seeing a combined P-E bid as the most likely path... https://seekingalpha.com/news/715791?source=tweet\" data-url=\"https://seekingalpha.com/news/715791\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715781\" data-ts=\"1355329091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOLC\" target=\"_blank\">VOLC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715781\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volcano Corp. (VOLC -1.8%) slips today after Credit Suisse downgraded the shares to Neutral and...</a></h4><p>Volcano Corp. (<a href=\"https://seekingalpha.com/symbol/VOLC\" title=\"Volcano Corporation\">VOLC</a> <font color=\"red\">-1.8%</font>) slips today after Credit Suisse <a href=\"http://www.streetinsider.com/Downgrades/Credit+Suisse+Downgrades+Volcano+Corp.+%28VOLC%29+to+Neutral/7941740.html\" target=\"_blank\">downgraded the shares</a> to Neutral and cut its price target from $32.00 to $27.00 . The firm says there's little clarity on its upcoming M&amp;A issues, and <a href=\"https://seekingalpha.com/symbol/VOLC\" title=\"Volcano Corporation\">VOLC</a> will have to execute solidly in order to create shareholder value. There's potential for further dilution if funds are spent on earlier stage/limited revenue assets.</p><div class=\"tiny-share-widget\" data-id=\"715781\" data-linked=\"Volcano Corp. (VOLC -1.8%) slips today after Credit Suisse downgraded the shares to Neutral and...\" data-tweet=\"$VOLC - Volcano Corp. (VOLC -1.8%) slips today after Credit Suisse downgraded the shares to Neutral and cut its price target from $32.00 to $27.00 . The firm says there&#39;s little clarity on its upcoming M&amp;A issues, and VOLC will have to execute solidly i... https://seekingalpha.com/news/715781?source=tweet\" data-url=\"https://seekingalpha.com/news/715781\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715711\" data-ts=\"1355327845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRK.B\" target=\"_blank\">BRK.B</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715711\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on the Berkshire (BRK.B +2.3%) buyback: The seller of the $1.2B in shares reportedly may be...</a></h4>More on the Berkshire (<a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a> <font color=\"green\">+2.3%</font>) <a href=\"https://seekingalpha.com/currents/post/715521\" target=\"_blank\">buyback</a>: The seller of the $1.2B in shares reportedly may be <a href=\"http://www.streetinsider.com/Insider+Trades/David+Gottesman+Said+to+Be+Seller+or+Berkshire+Class+A+%28BRKA%29+Stock%3B+Could+Save+%24300M+on+Tax+Bill/7942616.html\" target=\"_blank\">board member David Gottesman</a>. The sale could potentially save Gottesman hundreds of millions of dollars should Buffett get his wish of higher taxes next year.<div class=\"tiny-share-widget\" data-id=\"715711\" data-linked=\"More on the Berkshire (BRK.B +2.3%) buyback: The seller of the $1.2B in shares reportedly may be...\" data-tweet=\"$BRK.B $BRK.A - More on the Berkshire (BRK.B +2.3%) buyback: The seller of the $1.2B in shares reportedly may be board member David Gottesman. The sale could potentially save Gottesman hundreds of millions of dollars should Buffett get his wish of highe... https://seekingalpha.com/news/715711?source=tweet\" data-url=\"https://seekingalpha.com/news/715711\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715661\" data-ts=\"1355326659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTWO\" target=\"_blank\">TTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715661\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Take-Two Interactive (TTWO +3.8%) has jumped after being upgraded to Overweight by Piper. Its PT...</a></h4>Take-Two Interactive (<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a> <font color='green'>+3.8%</font>) has jumped after being <a href=\"http://www.streetinsider.com/Upgrades/Piper+Jaffray+Upgrades+Take-Two+Interactive+%28TTWO%29+to+Overweight/7941669.html\" target=\"_blank\">upgraded to Overweight</a> by Piper. Its PT is raised to $18 from $12. Though near-term business conditions are bleak, Take-Two shares have <a href=\"http://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1354914000000&amp;chddm=33715&amp;chls=IntervalBasedLine&amp;q=NASDAQ:TTWO&amp;ntsp=0&amp;ei=XqTIUJCbEYakiQKr8QE\" target=\"_blank\">slowly rallied</a> since August on hopes the arrival of <em>Grand Theft Auto V</em> and <em>Bioshock Infinite</em> will drive a 2013 rebound.<div class=\"tiny-share-widget\" data-id=\"715661\" data-linked=\"Take-Two Interactive (TTWO +3.8%) has jumped after being upgraded to Overweight by Piper. Its PT...\" data-tweet=\"$TTWO - Take-Two Interactive (TTWO +3.8%) has jumped after being upgraded to Overweight by Piper. Its PT is raised to $18 from $12. Though near-term business conditions are bleak, Take-Two shares have slowly rallied since August on hopes the arrival of ... https://seekingalpha.com/news/715661?source=tweet\" data-url=\"https://seekingalpha.com/news/715661\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715651\" data-ts=\"1355326452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715651\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix&#39;s (NFLX +3.4%) price target is upped to $105 from $80 by Morgan Stanley&#39;s Scott Devitt,...</a></h4><p>Netflix's (<a href=\"https://seekingalpha.com/symbol/NFLX\" title=\"Netflix, Inc.\">NFLX</a> <font color=\"green\">+3.4%</font>) price target is <a target=\"_blank\" href=\"http://www.marketwatch.com/story/netflix-target-upped-to-105-by-morgan-stanley-2012-12-12?siteid=yhoof2\">upped to $105</a> from $80 by Morgan Stanley's Scott Devitt, who is a big fan of last week's <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/699331\">deal with Disney</a>. \"(Netflix is) on course to potentially disrupt the long-standing premium cable ecosystem.\"</p><div class=\"tiny-share-widget\" data-id=\"715651\" data-linked=\"Netflix&#39;s (NFLX +3.4%) price target is upped to $105 from $80 by Morgan Stanley&#39;s Scott Devitt,...\" data-tweet=\"$NFLX - Netflix&#39;s (NFLX +3.4%) price target is upped to $105 from $80 by Morgan Stanley&#39;s Scott Devitt, who is a big fan of last week&#39;s deal with Disney. &quot;(Netflix is) on course to potentially disrupt the long-standing premium cable ecosystem.&quot; https://seekingalpha.com/news/715651?source=tweet\" data-url=\"https://seekingalpha.com/news/715651\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715621\" data-ts=\"1355326139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715621\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also...</a></h4><p>Ziopharm Oncology (<a href=\"https://seekingalpha.com/symbol/ZIOP\" title=\"ZIOPHARM Oncology, Inc.\">ZIOP</a> <font color=\"red\">-3.4%</font>) slips on a <a href=\"http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+ZIOPHARM+Oncology+%28ZIOP%29+to+Hold+on+Increased+Risks/7941681.html\" target=\"_blank\">downgrade to Hold</a> at Jefferies morning. The firm also cut its price target on the stock to $4 from $7 a share, citing increased clinical risks after the firm met with oncology experts to discuss <a href=\"https://seekingalpha.com/symbol/ZIOP\" title=\"ZIOPHARM Oncology, Inc.\">ZIOP</a>'s palifosfamide. The discussions indicate a sub-50% probability the drug will meet its OS endpoint, which is necessary for FDA approval.</p><div class=\"tiny-share-widget\" data-id=\"715621\" data-linked=\"Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also...\" data-tweet=\"$ZIOP - Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also cut its price target on the stock to $4 from $7 a share, citing increased clinical risks after the firm met with oncology experts to discuss ZIOP&#39;s p... https://seekingalpha.com/news/715621?source=tweet\" data-url=\"https://seekingalpha.com/news/715621\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715611\" data-ts=\"1355325718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YELP\" target=\"_blank\">YELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715611\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yelp (YELP +2.1%) is higher after getting started at Outperform by Credit Suisse, and at Neutral...</a></h4>Yelp (<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a> <font color='green'>+2.1%</font>) is higher after getting started at Outperform by <a href=\"http://www.streetinsider.com/New+Coverage/Credit+Suisse+Starts+Yelp+%28YELP%29+at+Outperform/7941556.html\" target=\"_blank\">Credit Suisse</a>, and at Neutral by <a href=\"http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Yelp+%28YELP%29+at+Neutral/7941555.html\" target=\"_blank\">JPMorgan</a>. A volatile name since its IPO, Yelp has <a href=\"http://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1355346000000&amp;chddm=6976&amp;chls=IntervalBasedLine&amp;q=NYSE:YELP&amp;ntsp=0&amp;ei=C6DIUMCOEPS1iALl-gE\" target=\"_blank\">barely moved</a> in recent weeks.<div class=\"tiny-share-widget\" data-id=\"715611\" data-linked=\"Yelp (YELP +2.1%) is higher after getting started at Outperform by Credit Suisse, and at Neutral...\" data-tweet=\"$YELP - Yelp (YELP +2.1%) is higher after getting started at Outperform by Credit Suisse, and at Neutral by JPMorgan. A volatile name since its IPO, Yelp has barely moved in recent weeks. https://seekingalpha.com/news/715611?source=tweet\" data-url=\"https://seekingalpha.com/news/715611\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715601\" data-ts=\"1355325274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMT\" target=\"_blank\">WMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715601\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wal-Mart (WMT -2.3%) bulls may have a buying opportunity as the stock slides following CEO Mike...</a></h4>Wal-Mart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> <font color=\"red\">-2.3%</font>) bulls may have a buying opportunity as the stock slides following CEO Mike Duke saying <a href=\"http://finance.fortune.cnn.com/2012/12/12/walmart-mike-duke/\" target=\"_blank\">75% of the store's shoppers</a> are aware of the fiscal cliff, up from 25% who knew about it before the election. Of the crowd who knows about it, 15% say it will affect their holiday spending.<div class=\"tiny-share-widget\" data-id=\"715601\" data-linked=\"Wal-Mart (WMT -2.3%) bulls may have a buying opportunity as the stock slides following CEO Mike...\" data-tweet=\"$WMT - Wal-Mart (WMT -2.3%) bulls may have a buying opportunity as the stock slides following CEO Mike Duke saying 75% of the store&#39;s shoppers are aware of the fiscal cliff, up from 25% who knew about it before the election. Of the crowd who knows about... https://seekingalpha.com/news/715601?source=tweet\" data-url=\"https://seekingalpha.com/news/715601\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715591\" data-ts=\"1355324798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AET\" target=\"_blank\">AET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715591\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aetna (NYSE:AET), which is holding its investor day, joins United Health and Cigna in providing...</a></h4><p>Aetna (NYSE:<a href=\"https://seekingalpha.com/symbol/AET\" title=\"Aetna, Inc.\">AET</a>), which is holding its <a href=\"http://www.aetna.com/investors-aetna/index.html\" target=\"_blank\">investor day</a>, joins United Health and Cigna in providing 2013 guidance that's <a href=\"http://www.bloomberg.com/news/2012-12-12/aetna-forecasts-2013-earnings-growth-below-estimates.html\" target=\"_blank\">below consensus</a>. Aetna forecasts EPS of at least $5.40 vs consensus of $5.52 and revenue growth of 9% to $38.6B vs $38.91B. Predicts that commercial-medical costs will rise 6.5%, the same as this year. BMO analyst Dave Shove says the outlook reflects \"management\u2019s cautious stance on guiding high.\"  Shares <font color=\"green\">+4.2%</font>.</p><div class=\"tiny-share-widget\" data-id=\"715591\" data-linked=\"Aetna (NYSE:AET), which is holding its investor day, joins United Health and Cigna in providing...\" data-tweet=\"$AET - Aetna (NYSE:AET), which is holding its investor day, joins United Health and Cigna in providing 2013 guidance that&#39;s below consensus. Aetna forecasts EPS of at least $5.40 vs consensus of $5.52 and revenue growth of 9% to $38.6B vs $38.91B. Predi... https://seekingalpha.com/news/715591?source=tweet\" data-url=\"https://seekingalpha.com/news/715591\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715541\" data-ts=\"1355324200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCMP\" target=\"_blank\">SCMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715541\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sucampo Pharma&#39;s (SCMP +6.1%) supplemental new drug application for its Rescula treatment to...</a></h4><p>Sucampo Pharma's (<a href=\"https://seekingalpha.com/symbol/SCMP\" title=\"Sucampo Pharmaceuticals, Inc.\">SCMP</a> <font color=\"green\">+6.1%</font>) supplemental new drug application for its Rescula treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension receives approval from the FDA. SCMP says it intends to commercialize the drug in Q1 2013.</p><div class=\"tiny-share-widget\" data-id=\"715541\" data-linked=\"Sucampo Pharma&#39;s (SCMP +6.1%) supplemental new drug application for its Rescula treatment to...\" data-tweet=\"$SCMP - Sucampo Pharma&#39;s (SCMP +6.1%) supplemental new drug application for its Rescula treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension receives approval from the FDA. SCMP says it intends to commercia... https://seekingalpha.com/news/715541?source=tweet\" data-url=\"https://seekingalpha.com/news/715541\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715521\" data-ts=\"1355323777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRK.B\" target=\"_blank\">BRK.B</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715521\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Berkshire Hathaway (NYSE:BRK.B) raises the value at which it will repurchase shares to 120% of...</a></h4><p>Berkshire Hathaway (NYSE:<a href=\"https://seekingalpha.com/symbol/BRK.B\" title=\"Berkshire Hathaway B\">BRK.B</a>) raises the value at which it will repurchase shares to 120% of book value, from 110% previously. Coincident with that news is the purchase of 9.2K shares of Class A stock at $131K each from the estate of a long-term shareholder. 120% of book is approximately the $87-$90 range for the \"B\" shares, which are <font color=\"green\">+1.6%</font> to $88.68.</p><div class=\"tiny-share-widget\" data-id=\"715521\" data-linked=\"Berkshire Hathaway (NYSE:BRK.B) raises the value at which it will repurchase shares to 120% of...\" data-tweet=\"$BRK.B $BRK.A - Berkshire Hathaway (NYSE:BRK.B) raises the value at which it will repurchase shares to 120% of book value, from 110% previously. Coincident with that news is the purchase of 9.2K shares of Class A stock at $131K each from the estate of a... https://seekingalpha.com/news/715521?source=tweet\" data-url=\"https://seekingalpha.com/news/715521\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715511\" data-ts=\"1355323594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715511\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the...</a></h4><p>Gilead Sciences (<a href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\">GILD</a> <font color=\"green\">+0.4%</font>) agrees to acquire YM BioSciences (<a href=\"https://seekingalpha.com/symbol/YMI\" title=\"\">YMI</a>) for $510M, with the $2.95/share offer representing an 81% premium to the latter's close of $1.63 yesterday. With the deal, Gilead will gain access to YM's blood and immune cell disorder drugs. Its lead drug candidate is CYT387 for treating myelofibrosis, a progressive, chronic bone marrow disease. YM shares <font color=\"green\">sky 78%</font>. (PR)</p><div class=\"tiny-share-widget\" data-id=\"715511\" data-linked=\"Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the...\" data-tweet=\"$GILD - Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the $2.95/share offer representing an 81% premium to the latter&#39;s close of $1.63 yesterday. With the deal, Gilead will gain access to YM&#39;s blood and immune cell ... https://seekingalpha.com/news/715511?source=tweet\" data-url=\"https://seekingalpha.com/news/715511\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715451\" data-ts=\"1355322871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JKS\" target=\"_blank\">JKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715451\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JinkoSolar (JKS +3.1%) opens higher after announcing a deal to supply 81MW worth of solar...</a></h4><p>JinkoSolar (<a href=\"https://seekingalpha.com/symbol/JKS\" title=\"JinkoSolar Holding Co., Ltd.\">JKS</a> <font color=\"green\">+3.1%</font>) opens higher after announcing a deal to supply 81MW worth of solar modules for a South African municipal project. Shipments will start in Q1, and the project is set to be completed before the end of Q4. Jinko took off last week after reaching a needed <a href=\"https://seekingalpha.com/currents/post/707221\" target=\"_blank\">$1B financing deal</a> with China Development Bank.</p><div class=\"tiny-share-widget\" data-id=\"715451\" data-linked=\"JinkoSolar (JKS +3.1%) opens higher after announcing a deal to supply 81MW worth of solar...\" data-tweet=\"$JKS - JinkoSolar (JKS +3.1%) opens higher after announcing a deal to supply 81MW worth of solar modules for a South African municipal project. Shipments will start in Q1, and the project is set to be completed before the end of Q4. Jinko took off last ... https://seekingalpha.com/news/715451?source=tweet\" data-url=\"https://seekingalpha.com/news/715451\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715411\" data-ts=\"1355322595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRL\" target=\"_blank\">CRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715411\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charles River Labs (NYSE:CRL) -5.1% premarket after providing 2013 earnings guidance below...</a></h4><p>Charles River Labs (NYSE:<a href=\"https://seekingalpha.com/symbol/CRL\" title=\"Charles River Laboratories International, Inc.\">CRL</a>) <font color=\"red\">-5.1%</font> premarket after providing 2013 earnings guidance below expectations, at $2.80-$2.90 per share vs. $3.01 consensus estimate. The drug research services provider also expects 2012 EPS to come in between the low end and the midpoint of its previously estimated range of $2.68-$2.73.</p><div class=\"tiny-share-widget\" data-id=\"715411\" data-linked=\"Charles River Labs (NYSE:CRL) -5.1% premarket after providing 2013 earnings guidance below...\" data-tweet=\"$CRL - Charles River Labs (NYSE:CRL) -5.1% premarket after providing 2013 earnings guidance below expectations, at $2.80-$2.90 per share vs. $3.01 consensus estimate. The drug research services provider also expects 2012 EPS to come in between the low e... https://seekingalpha.com/news/715411?source=tweet\" data-url=\"https://seekingalpha.com/news/715411\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715381\" data-ts=\"1355321712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715381\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Market preview: Stock futures are heading higher along with European stocks as the market...</a></h4><b>Market preview:</b> Stock futures are <a href=\"http://www.reuters.com/article/2012/12/12/markets-usa-stocks-idUSL1E8NC1ZU20121212\" target=\"_blank\">heading higher</a> along with European stocks as the market eagerly anticipates the announcement of more money printing from the Fed later today, although <a href=\"https://seekingalpha.com/currents/post/714791\" target=\"_blank\">not everyone's convinced</a> it's such a good thing. The S&amp;P benchmark is <font color=\"green\">+0.1%</font>. Eli Lilly <font color=\"red\">-3.6%</font> after delaying filing for approval of its Alzheimer's treatment and Molycorp is <font color=\"red\">-6%</font> after its CEO leaves. <a href=\"https://seekingalpha.com/currents/post/713931\" target=\"_blank\">Later</a>: FOMC, Treasury budget<div class=\"tiny-share-widget\" data-id=\"715381\" data-linked=\"Market preview: Stock futures are heading higher along with European stocks as the market...\" data-tweet=\"Market preview: Stock futures are heading higher along with European stocks as the market eagerly anticipates the announcement of more money printing from the Fed later today, although not everyone&#39;s convinced it&#39;s such a good thing. The S&amp;P benchmark i... https://seekingalpha.com/news/715381?source=tweet\" data-url=\"https://seekingalpha.com/news/715381\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715351\" data-ts=\"1355321412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715351\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. OTC:BGMD +10%. Losers: RSOL -16%....</a></h4><b>Premarket gainers:</b> <a href=\"https://seekingalpha.com/symbol/YMI\" title=\"\">YMI</a> <font color=\"green\">+79%</font>. <a href=\"https://seekingalpha.com/symbol/DSTI\" title=\"DayStar Technologies, Inc.\">DSTI</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/SCMP\" title=\"Sucampo Pharmaceuticals, Inc.\">SCMP</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/ACAD\" title=\"ACADIA Pharmaceuticals Inc.\">ACAD</a> <font color=\"green\">+9%</font>. <a href=\"https://seekingalpha.com/symbol/BGMD\" title=\"BG Medicine, Inc.\">OTC:BGMD</a> <font color=\"green\">+10%</font>. <br><b>Losers:</b> RSOL <font color=\"red\">-16%</font>. <a href=\"https://seekingalpha.com/symbol/CIE\" title=\"Cobalt International Energy, Inc.\">CIE</a> <font color=\"red\">-11%</font>. MCP <font color=\"red\">-6%</font>.<div class=\"tiny-share-widget\" data-id=\"715351\" data-linked=\"Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. OTC:BGMD +10%. Losers: RSOL -16%....\" data-tweet=\"$GILD $GILD $DSTI - Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. OTC:BGMD +10%. Losers: RSOL -16%. CIE -11%. MCP -6%. https://seekingalpha.com/news/715351?source=tweet\" data-url=\"https://seekingalpha.com/news/715351\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715341\" data-ts=\"1355321208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCPIQ\" target=\"_blank\">MCPIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715341\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Despite the immediate negative reaction to the ouster of Molycorp (MCP) CEO Mark Smith - shares...</a></h4><p>Despite the immediate negative reaction to the <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/714231\">ouster</a> of Molycorp (MCP) CEO Mark Smith - shares <font color=\"red\">-5.5%</font> premarket - investors may come around to <a target=\"_blank\" href=\"http://www.bloomberg.com/news/2012-12-11/molycorp-appoints-karayannopoulos-as-ceo-after-mark-smith-exits.html\">a more positive view</a>. Smith \"had lost credibility\" with constituents, shareholders, potential investors and analysts, a J.P. Morgan analyst says; \"his ability to deal with the financials of an emerging company appeared to overwhelm him at times,\" says another.</p><div class=\"tiny-share-widget\" data-id=\"715341\" data-linked=\"Despite the immediate negative reaction to the ouster of Molycorp (MCP) CEO Mark Smith - shares...\" data-tweet=\"$MCPIQ - Despite the immediate negative reaction to the ouster of Molycorp (MCP) CEO Mark Smith - shares -5.5% premarket - investors may come around to a more positive view. Smith &quot;had lost credibility&quot; with constituents, shareholders, potential investo... https://seekingalpha.com/news/715341?source=tweet\" data-url=\"https://seekingalpha.com/news/715341\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715291\" data-ts=\"1355320429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLNY\" target=\"_blank\">CLNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715291\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NorthStar Realty Finance (NRF) prices its 25M share secondary at $6.40/share. The underwriters...</a></h4><p>NorthStar Realty Finance (NRF) prices its <a href=\"https://seekingalpha.com/currents/post/714141\" target=\"_blank\">25M share secondary</a> at $6.40/share. The underwriters have a 30-day option to purchase another 3.75M shares. The stock is <font color=\"red\">off 4.5%</font> premarket to $6.34. (PR)</p><div class=\"tiny-share-widget\" data-id=\"715291\" data-linked=\"NorthStar Realty Finance (NRF) prices its 25M share secondary at $6.40/share. The underwriters...\" data-tweet=\"$CLNY - NorthStar Realty Finance (NRF) prices its 25M share secondary at $6.40/share. The underwriters have a 30-day option to purchase another 3.75M shares. The stock is off 4.5% premarket to $6.34. (PR) https://seekingalpha.com/news/715291?source=tweet\" data-url=\"https://seekingalpha.com/news/715291\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715141\" data-ts=\"1355318023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715141\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate Technology (NASDAQ:STX) is downgraded to Sell at JPMorgan, which cites a revision to...</a></h4><p>Seagate Technology (NASDAQ:<a href=\"https://seekingalpha.com/symbol/STX\" title=\"Seagate Technology\">STX</a>) is <a href=\"http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Seagate+Technology+%28STX%29+to+Underweight/7941675.html\" target=\"_blank\">downgraded to Sell</a> at JPMorgan, which cites a revision to shrinkage from growth in expected hard disk drive unit demand in 2013. Shares <font color=\"red\">-3.6%</font> premarket. Western Digital (NYSE:<a href=\"https://seekingalpha.com/symbol/WDC\" title=\"Western Digital Corporation\">WDC</a>) <font color=\"red\">-1.1%</font> premarket.</p><div class=\"tiny-share-widget\" data-id=\"715141\" data-linked=\"Seagate Technology (NASDAQ:STX) is downgraded to Sell at JPMorgan, which cites a revision to...\" data-tweet=\"$STX $STX $WDC - Seagate Technology (NASDAQ:STX) is downgraded to Sell at JPMorgan, which cites a revision to shrinkage from growth in expected hard disk drive unit demand in 2013. Shares -3.6% premarket. Western Digital (NYSE:WDC) -1.1% premarket. https://seekingalpha.com/news/715141?source=tweet\" data-url=\"https://seekingalpha.com/news/715141\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"715121\" data-ts=\"1355317716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/715121\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eli Lilly (NYSE:LLY) -5.1% after saying it will carry out another Phase III trial of its...</a></h4><p>Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) <font color=\"red\">-5.1%</font> after saying it will carry out <a href=\"http://www.fiercebiotech.com/story/eli-lilly-ditches-fda-filing-alzheimers-hope-solanezumab/2012-12-12\" target=\"_blank\">another Phase III trial</a> of its solanezumab treatment in patients with mild symptoms of Alzheimer's disease,  and will delay applying for approval in the U.S. and Europe following meetings with regulators. The postponement is unlikely to surprise SA author Brian Wilson, who <a href=\"https://seekingalpha.com/currents/post/576421\" target=\"_blank\">pointed out</a> that apparent patient improvement in two previous studies was \"not statistically significant.\" (PR)</p><div class=\"tiny-share-widget\" data-id=\"715121\" data-linked=\"Eli Lilly (NYSE:LLY) -5.1% after saying it will carry out another Phase III trial of its...\" data-tweet=\"$LLY - Eli Lilly (NYSE:LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab treatment in patients with mild symptoms of Alzheimer&#39;s disease, and will delay applying for approval in the U.S. and Europe following meetings w... https://seekingalpha.com/news/715121?source=tweet\" data-url=\"https://seekingalpha.com/news/715121\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"714781\" data-ts=\"1355303526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/714781\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asian and European shares are broadly higher as markets lick their lips in anticipation of an...</a></h4>Asian and European shares are <a href=\"http://www.reuters.com/article/2012/12/12/markets-global-idUSL5E8NC3F820121212\" target=\"_blank\">broadly higher</a> as markets lick their lips in anticipation of an increased surge of liquidity from the Fed later today. Japan <font color=\"green\">+0.6%</font>, Hong Kong <font color=\"green\">+0.8%</font>, China <font color=\"green\">+0.4%</font>, India <font color=\"red\">-0.1%</font>. EU Stoxx 50 <font color=\"green\">+0.1%</font>, London <font color=\"green\">+0.1%</font>. Paris flat, Frankfurt <font color=\"green\">+0.3%</font>, Italy <font color=\"green\">+0.55%</font>, Madrid <font color=\"green\">+0.6%</font>.<div class=\"tiny-share-widget\" data-id=\"714781\" data-linked=\"Asian and European shares are broadly higher as markets lick their lips in anticipation of an...\" data-tweet=\"Asian and European shares are broadly higher as markets lick their lips in anticipation of an increased surge of liquidity from the Fed later today. Japan +0.6%, Hong Kong +0.8%, China +0.4%, India -0.1%. EU Stoxx 50 +0.1%, London +0.1%. Paris flat, Fra... https://seekingalpha.com/news/714781?source=tweet\" data-url=\"https://seekingalpha.com/news/714781\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 AM </div></div></li>","count":48,"message":null,"success":true,"today":{"start":1576645200,"end":1576731599,"str":"Wednesday, December 18, 2019"},"yesterday":{"start":1576558800,"end":1576645199}}